
Revolution Medicines soars after FDA approves pancreatic cancer drug RASONQUE with 60% death risk reduction.
Revolution Medicines received FDA approval for its pancreatic cancer drug RASONQUE, which showed a 60% reduction in death risk in Phase 3 trials. This approval marks the first broad RAS-targeted treatment for metastatic pancreatic cancer, a disease w...

